Atypical Antipsychotics

Applications Antipsychotic used in the treatment of schizophrenia. References Nourian, Z., et al.: Eur. J. Pharmacol., 596, 32 (2008), Karczewski, J., et al.: Biochem. Pharmacol., 77, 1602 (2009), Isoherranen, N., et al.: Chem. Res. Toxicol., 22, 294 (2009), Goetghebeur, P., et al.: Psychopharmacol., 202, 287 (2009),

Applications Zuclopenthixol Decanoate is used in the maintenance treatment of chronic schizophrenic patients. it is one of the three distinct formulations of Zuclopenthixol namely, zuclopenthixol dihydrochloride, zuclopenthixol acetate or Acuphase and zuclopenthixol decanoate. References Wistedt B, et al; Acta Psychiatr Scand. 1991 Jul;84(1):14-21Izmeth MG, et al; Pharmatherapeutica. 1988;5(4):217-27.

Applications A labelled metabolite of Quetiapine, which is used as an antipsychotic. References Onrust, S., et al.: CNS Drugs, 15, 329 (2001), Lin, S., et al.: J. Anal. Toxicol., 28, 443 (2004), Kirschbaum, K., et al.: Clin. Chem., 51, 1718 (2005), Kinon, B., et al.: J. Clin. Psychopharmacol., 26, 453 (2006),

Applications Labelled Asenapine. Asenapine is a combined serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related to Mianserin. Antipsychotic. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Meltzer, H. et al.: J. Pharmacol. Exp. Ther., 251, 238 (1989); Schotte, A. et al.: Brain Res., 631, 191 (1993); Andree, B. et al.: Psychopharmacology, 131, 339 (1997); Richelson, E. et al.: Life Sci., 68, 29 (2000);

Applications Risperidone 9-Ethylidenecarboxylate Hydrochloride, is the derivative of Risperidone (R525000), which is combined serotonin (5-HT2) and dopamine (D2) receptor antagonist, used for the treatment of schizophrenia, bipolar disorder and behavior problems in people with autism. References Tiberghien, F., et al.: Anticancer Drugs, 7, 568 (1996), Kansy, M., et al.: J. Med. Chem., 41, 1007 (1998), Kerns, E., et al.: J. Pharm. Sci., 90, 1838 (2001), Kerr, K., et al.: J. Biol. Chem., 276, 8657 (2001), Doran, A., et al.: Drug Metab. Dispos., 33, 165 (2005),